IPF Next-Gen Antifibrotics: LPA1, PDE4B, TNIK & Beyond
Strategic map of IPF antifibrotic pipeline: LPA1, PDE4B, TNIK, integrin, and Hedgehog targets with combination therapy rationale and preclinical POC.
Introduction
Treatment of idiopathic pulmonary fibrosis (IPF) took a major step forward with the 2014 approval of pirfenidone (Esbriet) and nintedanib (Ofev). However, while these drugs can slow the rate of lung function decline, they cannot stop fibrosis progression.
Roughly half of patients continue to progress on treatment, and the median survival after diagnosis remains 3–5 years. To break through this "progression barrier," as of April 2026 multiple agents with novel mechanisms are in clinical development.
This article provides a strategic overview of mechanism classes rather than individual drug reviews (see IPF treatment landscape 2025 and LPA1 antagonist details for those). The focus is on understanding why specific targets were chosen and how they might be combined.
1. Limitations of Current Therapy: Why "Slowing Down" Is Not Enough
Performance of Pirfenidone and Nintedanib
| Drug | Mechanism | FVC Decline Reduction | Limitations |
|---|---|---|---|
| Pirfenidone | TGF-β downstream signaling suppression, anti-inflammatory | ~50% reduction in annual FVC decline | Cannot halt progression. GI side effects limit dosing |
| Nintedanib | PDGFR/FGFR/VEGFR multi-kinase inhibition | ~50% reduction in annual FVC decline | Diarrhea is the primary dose-limiting factor. Hepatic monitoring required |
Unmet Needs
- Disease Modification: No drug achieves fibrosis stabilization or reversal
- Response Prediction: No biomarkers to predict which patients respond to which drug
- Combination Evidence: Safety data for pirfenidone + nintedanib combination remain limited
- PPF Expansion: The paradigm shift from IPF to PPF is underway, but PPF-specific therapies remain unestablished
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. The Mechanism of Fibrosis "Progression": Why It Cannot Be Stopped
IPF fibrosis progresses as a self-amplifying loop where multiple pathways compensate for each other. This is the fundamental reason why inhibiting a single target cannot halt progression.
Three-Layer Architecture of the Fibrotic Cascade
[Layer 1: Upstream Signals — Injury & Activation]
Epithelial injury → DAMP release → Immune cell recruitment
LPA / Hedgehog / Wnt activate fibroblasts
[Layer 2: Midstream Effectors — Fibroblast Transformation]
TGF-β/Smad → Myofibroblast differentiation (including EMT)
PDGF/FGF → Proliferation
Integrins → Latent TGF-β activation (positive feedback)
[Layer 3: Downstream Outcome — ECM Accumulation & Stiffening]
Excess collagen & fibronectin production
LOXL2 → Collagen cross-linking → ECM stiffening
Stiffened ECM → Mechanical signaling further activates fibroblasts (YAP/TAZ)
Key Point: Nintedanib targets Layer 2 kinases, and pirfenidone suppresses broad Layer 1–2 signals. However, Layer 1 upstream signals and Layer 3 feedback loops remain insufficiently covered.
3. Strategic Map of Next-Generation Targets
Class-Level Positioning
The following map shows which "layer" each next-generation drug targets.
| Class | Representative Compound | Target Layer | Mechanism | Development Stage |
|---|---|---|---|---|
| LPA1 receptor antagonism | Admilparant / BMS-986278 | Layer 1 | Blocks LPA-LPAR1 signaling → suppresses fibroblast recruitment & epithelial barrier dysfunction | Phase 3 (ALOFT-IPF, NCT06003426) |
| Selective PDE4B inhibition | Nerandomilast (BI 1015550, Jascayd) | Layer 1–2 | Elevates cAMP → suppresses myofibroblast differentiation + anti-inflammatory | Approved (IPF: 2025-10-07 / PPF: 2025-12-19, FDA) |
| TNIK inhibition | ISM001-055 (Rentosertib) | Layer 2 | Inhibits TNIK downstream of Wnt/TGF-β → suppresses EMT & proliferation | Phase 2 (GENESIS-IPF, Nat Med 2025) |
| AT2 receptor agonism | Buloxibutid (C21) | Layer 1 | AT2 receptor activation → antifibrotic, anti-inflammatory, tissue repair | Phase 2b (ASPIRE) |
| Hedgehog inhibition | ENV-101 (Taladegib) | Layer 1 | Blocks Sonic Hedgehog signaling → suppresses fibroblast activation | Phase 2b (WHISTLE-PF) |
| αv integrin inhibition | (Next-gen candidates in discovery) | Layer 2–3 | Prevents latent TGF-β activation → interrupts positive feedback loop | Phase 1–2 |
Why "Multi-Target" Is Necessary
Q: Isn't nintedanib already a multi-kinase inhibitor?
A: Yes, but it targets multiple kinases WITHIN the same pathway layer.
To simultaneously cover different "layers" of the fibrotic cascade,
combination of different drug CLASSES is needed.
Rationale for combination therapy: Coverage across Layer 1 (LPA1 or Hedgehog) + Layer 2 (existing drugs) + Layer 3 (integrin or LOXL2 inhibition) is a leading hypothesis for maximizing progression suppression. That said, no combination regimen has yet been shown to clinically "stop" IPF progression, and this remains a hypothesis awaiting clinical validation.
4. Deep Dive into Key Mechanism Classes
LPA1 Receptor Antagonism (Upstream Signal Blockade)
Lysophosphatidic acid (LPA) is a lipid mediator released from injured epithelial cells that, via the LPA1 receptor:
- Promotes fibroblast migration and activation
- Induces epithelial cell apoptosis
- Increases vascular permeability
The Phase 2 trial of BMS-986278 (INN: Admilparant, NCT04308681, Corte TJ et al., AJRCCM 2025;211:230-238, PMID 39393084) enrolled both IPF and PPF cohorts. In the IPF cohort (60 mg BID), 26-week FVC change was −1.2% vs placebo −2.7% (between-group difference non-significant), while the PPF cohort showed a 3.2 percentage-point absolute difference (95% CI 0.7–5.7, significant). Signal was also observed on a background of pirfenidone/nintedanib, providing a clinical hint that LPA1 targets a pathway distinct from existing therapies. Phase 3 ALOFT-IPF (NCT06003426, primary completion Oct 2026) and ALOFT-PPF are ongoing.
For details, see BMS-986278 (LPA1 antagonist) clinical and preclinical profile.
TNIK Inhibition (A Novel Target Discovered by AI)
TNIK (Traf2- and Nck-interacting kinase) is a unique kinase identified through AI-based target discovery:
- Positioned at the intersection (node) of Wnt and TGF-β signaling
- Controls myofibroblast differentiation and epithelial-mesenchymal transition (EMT)
- A target that is easily missed by conventional phenotypic screening
ISM001-055 (Rentosertib) is in Phase 2a (GENESIS-IPF, NCT05938920), which showed a 12-week FVC change of +98.4 mL (60 mg QD) vs −20.3 mL placebo (Nat Med 2025), making it a success story of AI-driven drug target discovery.
Lessons from Failures: Pamrevlumab and Bexotegrast
Two major Phase 3-stage failures provide critical context for next-generation antifibrotic development.
Pamrevlumab (CTGF/CCN2 neutralizing antibody, FibroGen) — ZEPHYRUS-1 Phase 3 failure (June 2023)
- Did not separate from placebo on the primary endpoint (52-week FVC change); development was discontinued in June 2023.
- CTGF/CCN2 is a downstream effector, and single-node blockade cannot cover multiple self-amplifying loops.
- This failure accelerated an industry-wide shift toward upstream signaling targets (LPA1, PDE4B, Hedgehog, AT2).
Bexotegrast (αvβ6/αvβ1 dual inhibitor, Pliant) — BEACON-IPF Phase 2b/3 discontinued (2025-03-03)
αvβ6 integrin was an important target involved in latent TGF-β activation. The Phase 2a trial INTEGRIS-IPF (NCT04396756) met its primary endpoint of safety/tolerability, and exploratory FVC analysis even showed a positive signal (Lancet Respir Med 2024, PMID 38843105).
However, the pivotal Phase 2b/3 BEACON-IPF (NCT06097260) trial was discontinued on March 3, 2025 on DSMB recommendation. The reason was not an efficacy miss but a safety/tolerability signal — an imbalance in unadjudicated IPF-related adverse events vs placebo (an early FVC efficacy signal had actually been observed). Program-level discontinuation was announced in June 2025.
Implications:
- αvβ6/αvβ1 dual inhibition faces a difficult long-term safety profile (IPF progression events are hard to distinguish from drug-related AEs without adjudication)
- The importance of evaluating effects on epithelial barrier function
- The need for biomarker-based patient selection and independent event adjudication committees
These two cases point to the value of combining multiple upstream-signal layers (LPA1 · Hedgehog · AT2) using different drug classes rather than single-effector inhibition.
5. Combination Therapy Outlook
Combination Strategies Under Investigation
| Combination Pattern | Rationale | Challenges |
|---|---|---|
| Nintedanib + LPA1 antagonist | Layer 2 + Layer 1 covering upstream + midstream | Being evaluated in ALOFT trial subgroup analysis |
| Nintedanib + Nerandomilast | Complementary kinase inhibition + cAMP elevation | Safety data needed |
| PDE4B inhibitor + AT2 agonist | Dual-axis: antifibrotic + tissue repair | Theoretical. No clinical evidence yet |
| Existing drug + LOXL2 inhibitor | Suppress ECM accumulation + prevent ECM cross-linking | LOXL2 inhibitor (simtuzumab) previously failed. Awaiting next-gen candidates |
Challenges of Combination Approaches
- Safety: Overlapping side effects of multiple antifibrotic agents (especially GI)
- Drug interactions: Risk of CYP enzyme inhibition/induction
- Clinical trial design: Placebo control ethically difficult (add-on to existing therapy is mandatory)
- Regulatory complexity: Both standalone and combination evidence required for each agent
6. Preclinical POC Strategy: Selecting the Right Animal Model
Matching Preclinical Models to the Mechanism of Action
For achieving POC (Proof of Concept) with next-generation drugs, selecting animal models appropriate to the target mechanism is crucial.
| Drug Class | Recommended Model | Rationale |
|---|---|---|
| LPA1 antagonist | BLM therapeutic dosing (Day 7–21) | LPA production persists from acute injury. Clear therapeutic intervention window |
| PDE4B inhibitor | BLM + inflammatory composite model | Evaluation of cAMP pathway's anti-inflammatory action during inflammatory phase is key |
| TNIK inhibitor | BLM therapeutic dosing + TGF-β Tg | Assessing the Wnt/TGF-β intersection. TGF-β overexpression model is appropriate |
| Integrin inhibitor | BLM + hydroxyproline quantification | Quantify TGF-β activation inhibition by collagen measurement |
| Hedgehog inhibitor | BLM therapeutic dosing | Hedgehog pathway activates during the fibrotic phase |
Combining Assessment Endpoints
Multiple evaluation methods are recommended for robust POC:
- Histological assessment: PSR staining + AI image analysis → Objective %Collagen Area quantification
- Biochemical assessment: Hydroxyproline quantification → Absolute collagen content
- Gene expression: Col1a1, αSMA, TGF-β1 by qPCR
- Lung function: Mouse FlexiVent for lung compliance measurement
- Biomarkers: Target-specific (e.g., plasma LPA concentration, cAMP levels)
7. Toward Precision Medicine: Biomarker-Driven Treatment Selection
Why "One Drug for All IPF Patients" Is Insufficient
Growing evidence suggests that the dominant driving mechanism of fibrosis differs among individual IPF patients:
- LPA-dominant type: High LPA concentration in bronchoalveolar lavage fluid (BALF) → LPA1 antagonist candidate
- Inflammation-dominant type: Inflammatory cytokine profile in BALF → PDE4B inhibitor candidate
- EMT-dominant type: Epithelial marker expression patterns → TNIK inhibitor candidate
Companion Biomarkers in Development
| Biomarker | Corresponding Drug Class | Measurement Method |
|---|---|---|
| Plasma LPA concentration | LPA1 antagonists | LC-MS/MS |
| KL-6 / SP-D | Disease activity monitoring | ELISA |
| PRO-C3 / C3M | Collagen turnover | ELISA |
| Gene expression profiles | General stratification | RNA-seq / NanoString |
[TIP] Biomarker evaluation at the preclinical stage directly feeds into clinical companion diagnostic development. It is recommended to include biomarker collection in POC study designs alongside efficacy endpoints.
Frequently Asked Questions (FAQ)
Is Nerandomilast classified as "next-generation"?
Nerandomilast (BI 1015550, trade name Jascayd) was FDA approved for IPF on October 7, 2025 and for PPF on December 19, 2025 (China NMPA also approved PPF on 2025-12-10), so it has now joined the ranks of established drugs. However, its selective PDE4B inhibition mechanism is distinct from conventional multi-kinase inhibition, making it mechanistically next-generation. This article focuses primarily on compounds still in the development pipeline.
Why was bexotegrast's Phase 2b/3 trial discontinued?
BEACON-IPF (NCT06097260) was halted on DSMB recommendation in March 2025, but this was not an efficacy miss — it was a safety/tolerability call based on an imbalance of IPF-related adverse events vs placebo. An early FVC efficacy signal had in fact been observed, so the broad αv (αvβ6/αvβ1 dual) strategy itself was not invalidated. Future approaches will likely depend on independent event adjudication committees and safer patient selection strategies that factor in epithelial barrier preservation.
When will combination therapy become available?
The ALOFT Phase 3 trial of BMS-986278 includes combination arms with existing drugs (nintedanib/pirfenidone). Based on results expected around 2027, the first combination therapy regimen could potentially be established.
Can preclinical POC predict clinical efficacy?
The bleomycin model is an imperfect mimic of IPF (it self-resolves), but remains the most widely used model for drug efficacy screening. For more clinically relevant assessment, therapeutic dosing designs (dosing initiated after Day 7) and multi-endpoint approaches are recommended.
Summary
| Key Point | Details |
|---|---|
| Current limitations | Existing drugs "slow" but cannot "stop" progression |
| Strategic direction | Combination strategies covering different "layers" of the fibrotic cascade |
| Nearest next-gen drugs | BMS-986278 (LPA1, Phase 3), Rentosertib (TNIK, Phase 2) |
| Key lesson | Failures of Pamrevlumab (ZEPHYRUS-1, 2023) and bexotegrast (BEACON-IPF, 2025) highlight limits of single-target strategies and the importance of long-term safety evaluation |
| Preclinical key | Mechanism-matched model selection + multiple endpoints + simultaneous biomarker evaluation |
| Future | Biomarker-driven precision medicine selecting the optimal drug for each patient |
Related Articles
- IPF Treatment Pipeline & Landscape 2025 — Detailed individual drug reviews
- Inhaled Treprostinil (Tyvaso): TETON-1/2 Results in IPF — Deep-dive on the prostacyclin strategy for IPF
- BMS-986278 (LPA1 Receptor Antagonist): Clinical and Preclinical Profile — Deep dive on the LPA1 antagonist
- IPF vs PPF: Common Mechanisms and Treatment Strategies for Progressive Fibrosis — Treatment paradigm shift from IPF to PPF
- Sirius Red Staining × AI Image Analysis — State-of-the-art quantification for preclinical fibrosis assessment
- Hydroxyproline Assay: Principle, Protocol & Collagen Quantification — Biochemical quantification for POC endpoints